Caladrius Biosciences (CLBS) Reports Q4 Loss of $0.73/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. VRTX
5. ON
6. CHKP
7. HNGE
8. INSP
9. RXRX
10. MTCH

Go back to Caladrius Biosciences (CLBS) Reports Q4 Loss of $0.73/Share

Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results

March 17, 2017 7:00 AM EDT

Annual revenue growth of 57% exceeds 2016 financial guidance

Conference call begins today at 8:30 am Eastern time

BASKING RIDGE, N.J., March 17, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS) (Caladrius or the Company), a cell therapy company with a select therapeutic development pipeline focused on immune modulation and a subsidiary, PCT, a development and manufacturing partner for the cell therapy industry, announced financial results for the three and twelve months ended December 31, 2016.2016 and 2017 Year to Date Highlights

PCT:

... More